Table 6 demonstrates that, as a group, the application of the panels of galectin-3+ HBME-1; galectin-3+ CK19, or HBME-1 +CK19 does not significantly increases the sensitivity or specificity for the distinction of benign vs. malignant thyroid lesions. Here, KRT19 is linked to cancer.